Here are the 10-K annual reports from Axe Compute Inc. (AGPU) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow AGPU and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AGPU filings page.
Axe Compute Inc. filed its annual report outlining a major pivot from oncology drug discovery to an AI GPU compute and digital asset model. The company now prioritizes its Compute Services and Treasury Management segment, providing access to a distributed network of over 435,000 GPUs for AI and high‑performance workloads.
A central element is a Treasury Strategy centered on Aethir’s ATH token. As of December 31, 2025, Axe Compute held 2.837 billion unlocked ATH valued at $24.4 million and had rights to 3.511 billion locked ATH valued at $15.5 million, for 6.348 billion ATH and future rights at a reference price of $0.0086.
To fund this shift, the company closed October 2025 PIPE transactions totaling approximately $343.5 million in cash and in‑kind ATH contributions, and executed a 1‑for‑15 reverse stock split. It also rebranded from Predictive Oncology Inc. to Axe Compute Inc. and regained compliance with Nasdaq stockholders’ equity and bid‑price requirements.
The legacy Drug Discovery Services business, including the PEDAL AI platform and 3D tumor models, continues to operate but is deemed non‑core. In early 2026, the board began exploring strategic alternatives for this business while also appointing a new CEO and adding directors to support the AI compute focus.